z-logo
open-access-imgOpen Access
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Author(s) -
R.W. Birkinshaw,
Jianan Gong,
Chu Luo,
D Lio,
Christine White,
Mary Ann Anderson,
Piers Blombery,
Guillaume Lessène,
Ian J. Majewski,
Rachel Thijssen,
Andrew W. Roberts,
David C.S. Huang,
Peter M. Colman,
P.E. Czabotar
Publication year - 2019
Publication title -
nature communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.559
H-Index - 365
ISSN - 2041-1723
DOI - 10.1038/s41467-019-10363-1
Subject(s) - venetoclax , mutant , mutation , cancer research , apoptosis , drug resistance , computational biology , medicine , genetics , biology , chemistry , chronic lymphocytic leukemia , gene , leukemia
Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-2 mutation (G101V) in some patients failing therapy. To understand the molecular basis of this acquired resistance we describe the crystal structures of venetoclax bound to both BCL-2 and the G101V mutant. The pose of venetoclax in its binding site on BCL-2 reveals small but unexpected differences as compared to published structures of complexes with venetoclax analogues. The G101V mutant complex structure and mutant binding assays reveal that resistance is acquired by a knock-on effect of V101 on an adjacent residue, E152, with venetoclax binding restored by a E152A mutation. This provides a framework for considering analogues of venetoclax that might be effective in combating this mutation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here